Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 5:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Proton Radiation Therapy Clear all
Completed Not applicable Interventional Results available

Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma

NCT00976898
View directory record Official record
Conditions
Liver Cancer
Interventions
Proton Beam Irradiation
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
4
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 26, 2026, 5:37 AM EDT
Active, not recruiting No phase listed Observational

Accurate Point of Care Liver Disease Diagnostics

NCT05986916
View directory record Official record
Conditions
NAFLD, Nonalcoholic Fatty Liver
Interventions
Liverscope® exam, MR exam, FibroScan® exam (optional), Blood draw, Body measurements, Questionnaires
Diagnostic Test · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 26, 2026, 5:37 AM EDT
Completed Phase 1 Interventional

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

NCT02655614
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 26, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

The Role Of Omega-3 Fatty Acids In Adolescent Depression

NCT00962598
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Omega 3 Fatty Acids, Corn oil
Drug · Dietary Supplement
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years to 19 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Sep 26, 2026, 5:37 AM EDT
Active, not recruiting Not applicable Interventional

Ultrahypofractionation and Normal Tissue Toxicity

NCT05912231
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Breast Cancer Stage II, Breast Cancer Stage III, Myocardial Fibrosis
Interventions
Accelerated Proton Beam Radiation Therapy (PBT), Accelerated Photon Radiation Therapy (XRT)
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 26, 2026, 5:37 AM EDT
Recruiting Phase 2 Interventional

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

NCT05873712
View directory record Official record
Conditions
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Transformed
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Fludarabine, Leukapheresis, Lisocabtagene Maraleucel, Lymph Node Biopsy, Positron Emission Tomography, Zanubrutinib
Procedure · Drug · Biological
Lead sponsor
Aseel Alsouqi
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
New York, New York • Columbus, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 26, 2026, 5:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

NCT01076231
View directory record Official record
Conditions
Stage IIIA Non-small Cell Lung Cancer
Interventions
proton beam radiation therapy, cisplatin, etoposide, therapeutic conventional surgery
Radiation · Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 26, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

NCT05055128
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy
Drug
Lead sponsor
Cinclus Pharma Holding AB
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 26, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)

NCT01854554
View directory record Official record
Conditions
Brain Cancer
Interventions
IMPT, IMRT, Cognitive Tests, Questionnaires
Radiation · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 26, 2026, 5:37 AM EDT
Terminated Phase 2 Interventional

68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

NCT04928820
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Sep 26, 2026, 5:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants

NCT07329972
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ZN-A-1041 Formulation 1, ZN-A-1041 Formulation 2, Rabeprazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 26, 2026, 5:37 AM EDT
Recruiting Not applicable Interventional

LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)

NCT04699773
View directory record Official record
Conditions
Glioma, Glioblastoma, Brain Tumor
Interventions
LITT, Hypofractionated Radiation Therapy
Procedure · Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 26, 2026, 5:37 AM EDT
Completed Not applicable Interventional

18F-FDG PET-MRI for Planning and Follow-Up of Patients With Spine Tumors Treated With Spine Stereotactic Radiosurgery

NCT05174026
View directory record Official record
Conditions
Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Bone
Interventions
Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 26, 2026, 5:37 AM EDT
Active, not recruiting Phase 1 Interventional

OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma

NCT03587038
View directory record Official record
Conditions
Glioblastoma
Interventions
OKN 007, Temozolomide, Photon/Proton IMRT
Drug · Radiation
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 26, 2026, 5:37 AM EDT
Completed Phase 4 Interventional Results available

Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study

NCT00693225
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Omeprazole/sodium bicarbonate
Drug
Lead sponsor
Yvonne Romero
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Sep 26, 2026, 5:37 AM EDT
Completed Early Phase 1 Interventional

BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy

NCT05250895
View directory record Official record
Conditions
BCLC Stage a Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatocellular Carcinoma
Interventions
18F-Fluoromisonidazole, Biopsy, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Positron Emission Tomography
Other · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 26, 2026, 5:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Bipolar Depression Before and After Lamotrigine Treatment

NCT01042496
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lamotrigine, 1H-MR
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 26, 2026, 5:37 AM EDT
Completed Not applicable Interventional Results available

Proton Beam Radiation Therapy in Treating Young Patients Who Have Undergone Biopsy or Surgery for Medulloblastoma or Pineoblastoma

NCT00105560
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Long-term Effects Secondary to Cancer Therapy in Children
Interventions
radiation therapy
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
3 Years to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Sep 26, 2026, 5:37 AM EDT
Recruiting Phase 2 Interventional

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

NCT04900623
View directory record Official record
Conditions
HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage, HPV-Related Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic Stage
Interventions
NavDx HPV ctDNA Testing, Radiotherapy, Chemotherapy drug
Device · Radiation · Drug
Lead sponsor
Jonathan Schoenfeld, MD, MPH
Other
Eligibility
22 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 26, 2026, 5:37 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

NCT02208362
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma, Refractory Glioblastoma, Refractory Malignant Glioma, Refractory WHO Grade II Glioma, Refractory WHO Grade III Glioma
Interventions
Arm 1: IL13Ra2-specific CAR Tcm cells, Arm 2: IL13Ra2-specific CAR Tcm cells, Arm 3: IL13Ra2-specific CAR Tcm cells, Arm 4: IL13Ra2-specific CAR Tcm cells, Arm 5: IL13Ra2-specific CAR Tn/mem cells, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging, Quality-of-Life Assessment
Biological · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 26, 2026, 5:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants

NCT02475161
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42847922, Rabeprazole
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 26, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

Proton Re-Irradiation for Recurrent Head and Neck Cancer

NCT03217188
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
conventionally fractionated full dose re-irradiation, hypofractionated palliative re-irradiation
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 26, 2026, 5:37 AM EDT
Completed No phase listed Observational Results available

[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers

NCT02108457
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
[18F]Fluorothymidine (FLT) PET/CT Imaging
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 26, 2026, 5:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolism in the Human Brain Following Consumption of a Keto-ester in Alcohol Use Disorder (AUD) With Proton Magnetic Resonance Spectroscopic Imaging (MRSI)

NCT05937893
View directory record Official record
Conditions
BHB Transport, Alcohol Use Disorder
Interventions
Keto-ester followed by Magnetic Resonance Spectroscopic Imaging (MRSI) scans
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 26, 2026, 5:37 AM EDT